Randomised clinical trial: a placebo‐controlled study of intravenous golimumab induction therapy for ulcerative colitis

BACKGROUND: Tumour necrosis factor alpha (TNFα)‐antagonism effectively treats ulcerative colitis (UC). The golimumab clinical programme evaluated subcutaneous (SC) and intravenous (IV) induction, and SC maintenance regimens, in TNFα‐antagonist‐naïve patients with moderate‐to‐severe active UC despite...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Aliment Pharmacol Ther
Main Authors: Rutgeerts, P., Feagan, B. G., Marano, C. W., Padgett, L., Strauss, R., Johanns, J., Adedokun, O. J., Guzzo, C., Zhang, H., Colombel, J.‐F., Reinisch, W., Gibson, P. R., Sandborn, W. J.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2015
Teme:
Randomised Clinical Trial
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4755132/
https://ncbi.nlm.nih.gov/pubmed/26119226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.13291
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki